The Maudsley prescribing guidelines in psychiatry / David Taylor, Carol Paton, Shitij Kapur.

Format:

Book

Author/Creator:

Taylor, David, 1963- author.

Paton, Carol, author.

Kapur, Shitij, author.

Contributor:

South London and Maudsley NHS Trust, issuing body.

Language:

English

Subjects (All):

Psychopharmacology.

Psychotropic drugs.

Drugs--Prescribing.

Drugs.

Physical Description:

1 online resource (2455 p.)

Edition:

12th edition.

Place of Publication:

West Sussex, England : Wiley Blackwell, 2015.

Language Note:

English

Summary:

The fully updated 12th edition of an essential reference for anyone responsible for prescribing drugs for patients with mental health disorders. A well-respected and widely-used source of information on which drugs to prescribe, which side effects to look out for, how best to augment or switch drugs, and more Provides concise reviews of psychiatric disorders and relevant psychopharmacology, along with general guidance based on the data reviewed and current clinical practice Includes specific guidance for schizophrenia, bipolar disorder, depression, anxiety, substance abuse, and special pop

Contents:

Intro

Title Page

Copyright Page

Contents

Preface

Acknowledgements

Notes on using The Maudsley Prescribing Guidelines

List of abbreviations

Chapter 1 Plasma level monitoring of psychotropic drugs

Interpreting sample results

Amisulpride

Aripiprazole

Clozapine

Olanzapine

Quetiapine (IR)

Risperidone

References

Acting on clozapine plasma concentration results

Interpreting post-mortem blood concentrations

Chapter 2 Schizophrenia

Antipsychotic drugs

General introduction

Classification

Choosing an antipsychotic

Relative efficacy

General principles of prescribing

Minimum effective doses

Further reading

Quick reference for licensed maximum doses

Equivalent doses

High-dose antipsychotics: prescribing and monitoring

Efficacy

Adverse effects

Prescribing high-dose antipsychotics

Antipsychotic prophylaxis

First episode of psychosis

Multi-episode schizophrenia

Adherence to antipsychotic treatment

Dose for prophylaxis

How and when to stop

Key points that patients should know

Alternative views

Combined antipsychotics

Summary

Negative symptoms

Recommendations

Monitoring

Relative adverse effects - a rough guide

Treatment algorithms for schizophrenia

Notes

First-generation antipsychotics - place in therapy

Omega-3 fatty acid (fish oils) in schizophrenia

New and developing drugs to treat schizophrenia

Further refined dopamine-related antipsychotics

Non-dopamine approaches to antipsychotic effect

Add-on treatments for schizophrenia

References.

NICE guidelines for the treatment of schizophrenia

NICE guidelines - a summary

Antipsychotic response - to increase the dose, to switch, to add or just wait - what is the right move?

When to increase the dose?

Dose-response observations

Plasma level variations

Treatment choices

Summary - when treatment fails

Antipsychotic long-acting injections

Advice on prescribing LAIs

Differences between LAIs

Intramuscular anticholinergics and LAIs

Depot antipsychotics - pharmacokinetics

Management of patients on long-term depots

Aripiprazole LAI

Olanzapine LAI

Switching

Post-injection syndrome

Paliperidone palmitate LAI

Risperidone LAI

ANTIPSYCHOTICS - ADVERSE EFFECTS

Extrapyramidal side-effects

Akathisia

Weight gain

Treatment of drug-induced weight gain

Treatment and prevention

Tardive dyskinesia

Treatment - first steps

Treatment - additional agents

Treatment - other possible options

Neuroleptic malignant syndrome

Catatonia

QT prolongation

Introduction

Other ECG changes

Quantifying risk

Other risk factors

ECG monitoring

Metabolic inhibition

Other cardiovascular risk factors

Dyslipidaemia

Effect of antipsychotic drugs on lipids

Screening

Treatment of dyslipidaemia

Diabetes and impaired glucose tolerance

Schizophrenia

Antipsychotics

First-generation antipsychotics

Second-generation antipsychotics.

Predicting antipsychotic-related diabetes

Treatment of antipsychotic-related diabetes

Hypertension

Hyponatraemia

Hyperprolactinaemia

Prolactin concentration interpretation

Treatment

Sexual dysfunction

Effects of psychosis

Effects of antipsychotic drugs

Pneumonia

Switching antipsychotics

REFRACTORY SCHIZOPHRENIA AND CLOZAPINE

Clozapine - dosing regimen

Optimising clozapine treatment

Using clozapine alone

Clozapine augmentation

Alternatives to clozapine

Re-starting clozapine after a break in treatment

Reference

Initiation of clozapine for community-based patients

Contraindications to community initiation

Suitability for community initiation

Initial work-up

Mandatory blood monitoring and registration

Dosing

Switching from other antipsychotics

Serious cardiac adverse effects

CLOZAPINE - ADVERSE EFFECTS

Common adverse effects

Clozapine: uncommon or unusual adverse effects

Clozapine: serious haematological and cardiovascular adverse effects

Agranulocytosis, thromboembolism, cardiomyopathy and myocarditis

Thromboembolism

Myocarditis and cardiomyopathy

Clozapine-induced hypersalivation

Clozapine-induced gastrointestinal hypomotility (CIGH)

Prevention and simple management of CIGH

Management of suspected acute CIGH

Clozapine re-challenge following severe constipation

Clozapine, neutropenia and lithium

Risk of clozapine-induced neutropenia.

Benign ethnic neutropenia (BEN)

Effect of lithium on the WCC

Case reports

Other potential benefits of lithium-clozapine combinations

Agranulocytosis

Management options

Granulocyte-colony stimulating factor

Clozapine and chemotherapy

Chapter 3 Bipolar affective disorder

Lithium

Mechanism of action

Indications

Lithium and suicide

Plasma levels

Formulations

Lithium toxicity

Pre-treatment tests

On-treatment monitoring

Discontinuation

Interactions with other drugs

Valproate

Use in women of child-bearing age

Carbamazepine

Antipsychotics in bipolar disorder

Treatment of acute mania or hypomania

Bipolar depression

Meta-analysis in bipolar depression

Summary of drug choice

Rapid-cycling bipolar affective disorder

Prophylaxis in bipolar affective disorder

NICE recommendations

Summary: prophylaxis in bipolar affective disorder

Physical monitoring for people with bipolar affective disorder

Chapter 4 Depression and anxiety

Basic principles of prescribing in depression

Official guidance on the treatment of depression

NICE guidelines: a summary

Antidepressants: general overview

Effectiveness

Onset of action.

Choice of antidepressant and relative side-effects

Drug interactions

Suicidality

Duration of treatment

Next step treatments

Use of antidepressants in anxiety spectrum disorders

St John's wort

Evidence for SJW in the treatment of depression

Recognised minimum effective doses of antidepressants

Drug treatment of depression

Treatment of refractory depression

Treatment of refractory depression: first choice

Treatment of refractory depression: second choice

Treatment of refractory depression: other reported treatments

Treatment of refractory depression: sequence of treatments - summary

Psychotic depression

Electroconvulsive therapy and psychotropic drugs

Psychostimulants in depression

Post-stroke depression

Prophylaxis

Post-stroke depression - recommended drugs

Treatment of depression in the elderly

Antidepressant discontinuation symptoms

What are discontinuation symptoms?

Clinical relevance

Who is most at risk?

How to avoid discontinuation symptoms

How to treat discontinuation symptoms

Antidepressant prophylaxis

First episode

Recurrent depression

Antidepressants: alternative routes of administration

Alternative antidepressant delivery methods

Antidepressants: swapping and stopping

General guidelines

Drug interactions with antidepressants.

Pharmacodynamic interactions.

Notes:

Description based upon print version of record.

Includes bibliographical references at the end of each chapters and index.

Description based on print version record.

ISBN:

1-118-75459-X

1-118-75457-3

OCLC:

899114040